Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-120
SponsorNational Cancer Institute (NCI)

About this trial

Background:

Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS. Researchers want to learn more through this natural history study so they can develop better treatments.

Objective:

To study the natural course of MDS and MDS/myeloproliferative neoplasms (MPN) and collect biological samples that can help researchers understand the disease.

Eligibility:

People with suspected or confirmed MDS or MDS/MPN. Healthy donors are also needed. They can be people who are scheduled to donate bone marrow at NIH for a relative, or they may be providing bone marrow in another study.

Design:

Participants will be screened with a medical history.

Participants will have a physical exam. They will give blood and urine samples. They will discuss their symptoms, medications, and ability to perform their normal activities. They will complete surveys about how they are feeling.

Participants will have a bone marrow biopsy. A needle will be inserted through a small cut. Bone marrow will be removed. A small piece of bone may be removed.

Participants may have an optional skin biopsy.

Participants may give optional saliva and stool samples. They may collect these samples at home and mail them to NIH.

Participants may undergo optional apheresis. One or two needles or intravenous (IV) lines will be placed in their arm, neck, or groin veins. Blood will be removed. A machine will separate out the white cells. The rest of the blood will be returned to the participant.

Participants will be contacted for follow-up once a year for up to 20 years.

Healthy donors will have marrow collected for this study during their scheduled procedure with no follow-up.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

- MDS Participants

Either sex, any age.

Histologically or cytologically suspected or confirmed myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN), MDS/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis (MDS/MPN-RS-T), myelodysplastic syndromes/myeloproliferative neoplasms unclassified (MDS/MPN-U), chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), secondary acute myeloid leukemia (sAML) with antecedent MDS or MDS/MPN, or participants who have precursor conditions that are associated with a risk of progression to MDS, including but not limited to clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS).

Participants may have had any amount of prior therapy and may be receiving MDS-directed therapy at time of enrollment.

Disqualifiers

All Participants

Trial population

Either sex, any age for participants with MDS. Either sex, aged at least 1 month and \>=12kg for bone marrow controls.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,100 Participants
are grouped into 2 trial groups
Group A: Cohort 1
Group B: Cohort 2

Trial outcomes

Primary outcomes

1

characterize the natural history of myelodysplastic syndromes (MDS) and to assess overall and progression free survival

report the overall survival and progression status of participants

Time frame
5 years

Secondary outcomes

1

acquire biospecimens from MDS patients and controls to perform comprehensive research analyses

report the number of participants that have provided at least one of the biospecimens described in the protocol

Time frame
Ongoing throughout study

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.